Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism

American Heart Journal

Volumn 138, Issue 1 I, 1999, Pages 39-44

  Tebbe, U ^a   Graf, A ^a   Kamke, W ^a   Zahn, R ^a   Forycki, F ^a   Kratzsch, G ^a   Berg, G ^a  

^a Medizinische Klinik Lippe Detmold   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; RETEPLASE;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODYNAMIC MONITORING; HUMAN; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; MALE; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0032802952     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70243-7     Document Type: Article

References (22)

1. Dalen J, Alpert J. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975;17:259-70.
2. Rubinstein I, Murray D, Hoffstein V. Fatal pulmonary emboli in hospitalized patients. Arch Intern Med 1988;148:1425-6.
3. Lilienfeld D, Chan E, Ekland J, Landigran P, Marsh G. Mortality from pulmonary embolism in the United States 1962-1984. Chest 1990;98:1067-72.
4. Dalen J, Alpert J. Thrombolytic therapy for pulmonary embolism. Arch Intern Med 1997;157:2550-6.
5. Goldhaber SZ, Vaughan DE, Markis JE, Sehoyn AP, Meyerowitz M, Loscalzo J, et al. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986;2:886-9.
6. Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GVRK, Dawley D, et al. Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;2:293-8.
7. Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, et al. Paims 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator. Italian multicenter study 2. J Am Coll Cardiol 1992,20:520-6.
8. Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol 1992; 19:239-45.
9. Goldhaber SZ, Kessler CM, Heit JA, Elliott CG, Friedenberg WR, Heiselman DE, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992;20:24-30.
10. Verstraete M, Miller GAH, Bounameaux H, Charbonnier B, Colle JP, Lecorf G, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988;77:353-60.
11. Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol 1992,19:433-40.
12. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-8.
13. The GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. New Engl J Med 1997; 337:1118-23.
14. Miller G, Sutton G, Kerr J, Gibson R, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. BMJ 1971;2:681-4.
15. Riedel M, Rudolph W. Hämodynamik und Gasaustausch bei akuter Lungenembolie. Herz 1989;14:109-14.
16. Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simmoneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994,106:712-7.
17. Petitpretz P, Simoneau G, Cerrina J, Musset D, Dreyfers M, Vandenbroek M, et al. Effects of a single bolus of urokinase in patients with life-threatening pulmonary emboli; a descriptive trial. Circulation 1984;70:861-86.
18. Diehl JL, Meyer G, Igual J, Collignon MA, Giselbrecht M, Even P, et al. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol 1992;70:1477-80.
19. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990;98:1473-9.
20. Tebbe U, Seifried E, Carlsson J, Tanswell P. Thrombolysis using consecutive high dose bolus and infusion of alteplase in a patient with acute massive pulmonary embolism. Blood Coag Fibrinol 1992;3:475-80.
21. Goldhaber S, Agnelli C, Levine M, on behalf of the Bolus Alteplase Pulmonary Embolism Group. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. Chest 1994;106:718-24.
22. Goldhaber S, Feldstein M, Sors H. Two trials of reduced bolus alteplase in the treatment of pulmonary embolism. Chest 1994; 106:725-6.